# US 2019/0170770 A1 · Diagnostic Test to Exclude Significant Renal Injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0170770 A1
- Document ID: US20190170770A1
- Status: Published application
- Kind: A1
- Application number: 16/270,379
- Filed: 2019-02-07
- Published: 2019-06-06
- Earliest claimed: 2006-08-07
- Assignees: AntibodyShop A/S
- Applicants: Antibodyshop A/S
- Inventors: Lars Uttenthal; Kristian Bangert
- Web page: https://patentgrep.com/patent/US20190170770A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N 2800/7095: Inflammation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of treating a subject, who may be at risk of developing acute renal failure (ARF), with a diagnostic or therapeutic intervention that may provoke ARF, which comprises
(a) identifying the subject as belonging to a group of subjects who are at risk of developing ARF or belonging to a group of subjects who are not at risk of developing ARF by
i) determining the concentration of human neutrophil gelatinase associated lipocalin (NGAL) in a plasma sample from the subject, and
ii) identifying the subject as belonging to the group of subjects who are at risk of developing ARF where the concentration of NGAL is equal to or greater than a cutoff value and identifying the subject as belonging to the group of subjects who are not at risk of developing ARF where the concentration of NGAL is less than the cutoff value, wherein the cutoff value is a value between 150 ng/ml to 100 ng/ml; and
(b1) treating the subject at risk of developing ARF by maintaining and improving blood circulation to the subject's kidneys, eliminating any urinary flow obstructions in the subject, and/or avoiding the administration of a nephrotoxic drug to the subject, where the subject is identified as belonging to the group of subjects who are at risk of developing ARF, and
(b2) performing the diagnostic or therapeutic intervention that may provoke ARF where the subject is identified as belonging to the group of subjects who are not at risk of developing ARF.

### Claim 18 (depends on 17)

The method according to claim 17, which further comprises (c) monitoring the subject for the development of ARF.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the subject is identified as belonging to the group of subjects who are at risk of developing ARF.

### Claim 20 (depends on 18)

The method according to claim 18, wherein step (c) is performed after step (b1).

### Claim 21 (depends on 18)

The method according to claim 18, wherein step (c) comprises measuring and comparing NGAL levels in the subject.

### Claim 22 (depends on 21)

The method according to claim 21, wherein step (c) is performed at an interval subsequent to step (a).

### Claim 23 (depends on 17)

The method according to claim 17, wherein the diagnostic or therapeutic intervention is a surgical operation that may lead to ischemic injury of the kidney.

### Claim 24 (depends on 17)

The method according to claim 17, wherein the diagnostic or therapeutic intervention is administration of a nephrotoxic agent.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the nephrotoxic agent is an anti-neoplastic agent or a contrast agent.

### Claim 26

A method of treating a subject, who may be at risk of developing acute renal failure (ARF), with a diagnostic or therapeutic intervention that may provoke ARF, which comprises
(a) identifying the subject as belonging to a group of subjects who are at risk of developing ARF or belonging to a group of subjects who are not at risk of developing ARF by
i) determining the concentration of human neutrophil gelatinase associated lipocalin (NGAL) in a urine sample from the subject,
ii) identifying the subject as belonging to the group of subjects who are at risk of developing ARF where the concentration of NGAL is equal to or greater than a cutoff value and identifying the subject as belonging to the group of subjects who are not at risk of developing ARF where the concentration of NGAL is less than the cutoff value, wherein the cutoff value is a value between 100 ng/ml to 50 ng/ml; and
(b1) treating the subject at risk of developing ARF by maintaining and improving blood circulation to the subject's kidneys, eliminating any urinary flow obstructions in the subject, and/or avoiding the administration of a nephrotoxic drug to the subject, where the subject is identified as belonging to the group of subjects who are at risk of developing ARF, and
(b2) performing the diagnostic or therapeutic intervention that may provoke ARF where the subject is identified as belonging to the group of subjects who are not at risk of developing ARF.

### Claim 27 (depends on 26)

The method according to claim 26, which further comprises (c) monitoring the subject for the development of ARF.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the subject is identified as belonging to the group of subjects who are at risk of developing ARF.

### Claim 29 (depends on 27)

The method according to claim 27, wherein step (c) is performed after step (b1).

### Claim 30 (depends on 27)

The method according to claim 27, wherein step (c) comprises measuring and comparing NGAL levels in the subject.

### Claim 31 (depends on 30)

The method according to claim 30, wherein step (c) is performed at an interval subsequent to step (a).

### Claim 32 (depends on 26)

The method according to claim 26, wherein the diagnostic or therapeutic intervention is a surgical operation that may lead to ischemic injury of the kidney.

### Claim 33 (depends on 26)

The method according to claim 26, wherein the diagnostic or therapeutic intervention is administration of a nephrotoxic agent.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the nephrotoxic agent is an anti-neoplastic agent or a contrast agent.
